Overall, the accumulation of evidence supporting the BVS is a big part of Abbott's first-mover advantage. But the scrutiny can also be a drawback. A recent European postmarket data registry found that although the device performed well on most measures, the risk of the BVS being blocked by a blood clot is about twice as high as that for today's gold-standard drug-eluting stents.
More like a PE of 19......instItutions are buying CELG on future earrings not past earnings.
Yoko Ono was here long before you were ice ice baby he was I posting comentary that was irrelvent to NSPR ..both postive and negative,,, he is not a paid pumper that is a joke what is a joke is whatever you post here which is pure nonsense and the real joke. You are mindless worm with nothing better to do in your poor sad little patethic life where you probably live in a one bedroom apartment or at home with yoir mommy...lol
Blue Balls Mike = Liar
Mr. Alan W. Milinazzo joined NSPR in Jan. 2013 when stock was at $3.5 and share not $11.
Alan was being about $500k a year
Now he and the BOD are not taking any compensation because of some misteps by past management direction withpursuing Bare Mr=etal Stents instead of DES here in the US.
Alan is married and has been for a long time he is not out chasing women around nor does he have drug problem.
You have completely misrepresented your statements as they are out right lies ===You go in the idiot book with Ice -Ice baby
That is exactly what I am and I have a made a small fortune in the Biotech area over a 15 year period .... This position here is one of over 40 positions I own. I have spoken and met with Alan ... Expressed my concerns on several topics and feel comfortable that he and his management team can and will execute their plan of action. I think getting a partner in the DES market for the U.S. will be key to their success. If they are unable to get that accomplishedI I will sell my stock. However, I think they can get it done ....Good luck iced numb nuts
Not a paid pumper at all I am a retired money manager .... I have taken a position in this stock to the long side and will wait it out 3 years or more as will Sol Barer who has a very big investment here. Good Luck, nit wit
No it it won't go to .20 cents I will make a bet with you ! Selling was exhausted at about .28 ...Market cap here should be about $100 million when sales return in the EU and NSPR re enters the DES market in the US with a strategic partner ... Lots of money to be made here. Risk is not to the down side ...
We will see maybe .28 again and double bottom. Stock will Base for a while and move higher there is great potential here just have to let a strong management team execute their plan... I believe they can get this company to $200 million dollars in 3 to 4 years. It will not happen over night but it is very achieveable. Or they can sell this patented mesh technology to any number of company's which I have pointed out on this board ....they can still make a lot of money !! It will all be about ales growth and market pentration ... This company is not overly diluted at this point. Sales and market acceptance will tell the story.
hey ding #$%$ that .23 cents print was just panick selling and you would have been to be Houdini himself get any stock there... ice ice baby...But nice try as you are wrong with everything you say... It is entertaining however..lol
Please short this .35 stock camsham..lol
No hedge fund in their right mind would be shorting a stock this low ! The risk reward is not worth it
However, that said you will not see these stocks prices this low forever either. To get rich or make serious money it takes time.
1) Sales Ramping in Europe these guys can break even at $1 million a month in sales and that is nothing with the size of the market place they are going after and penetrating .
2) DES stent partner in US by 3 quarter.
3) Work on FDA protocol for clinical trial 2016 with Partner 2017. Hopefully upfront money and mile stones will provide cash they need to which will eliminate any further dilution.
4) Potential DES mesh covered stent into market by 2018 is US.
5) Potential sales easily $500 million.
6) NPSR will either sell company or be making great margins.
7) By 2018 to 2020 NSPR can be easily be a $20 to $30 dollar a share stock with $500 million in sales.
8) Soild Managament team that is important.
8) Management has skin in the game with many shares bought in open market and remember they want to get rich to.